image
Healthcare - Biotechnology - NASDAQ - US
$ 27.34
-1.16 %
$ 1.57 B
Market Cap
2.35
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one AGIO stock under the worst case scenario is HIDDEN Compared to the current market price of 27.3 USD, Agios Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one AGIO stock under the base case scenario is HIDDEN Compared to the current market price of 27.3 USD, Agios Pharmaceuticals, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one AGIO stock under the best case scenario is HIDDEN Compared to the current market price of 27.3 USD, Agios Pharmaceuticals, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart AGIO

image
$65.0$65.0$60.0$60.0$55.0$55.0$50.0$50.0$45.0$45.0$40.0$40.0$35.0$35.0$30.0$30.0$25.0$25.0$20.0$20.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
36.5 M REVENUE
36.07%
-426 M OPERATING INCOME
-8.75%
674 M NET INCOME
291.35%
-390 M OPERATING CASH FLOW
-31.68%
363 M INVESTING CASH FLOW
51.70%
14.4 M FINANCING CASH FLOW
165.82%
10.7 M REVENUE
19.70%
-125 M OPERATING INCOME
-21.62%
-96.5 M NET INCOME
-10.18%
-133 M OPERATING CASH FLOW
-58.12%
-49.2 M INVESTING CASH FLOW
-19.60%
4.84 M FINANCING CASH FLOW
83.62%
Balance Sheet Agios Pharmaceuticals, Inc.
image
Current Assets 966 M
Cash & Short-Term Investments 894 M
Receivables 4.11 M
Other Current Assets 67.8 M
Non-Current Assets 698 M
Long-Term Investments 0
PP&E 54.6 M
Other Non-Current Assets 643 M
53.73 %4.08 %3.28 %38.66 %Total Assets$1.7b
Current Liabilities 81.2 M
Accounts Payable 16.6 M
Short-Term Debt 33.6 M
Other Current Liabilities 31 M
Non-Current Liabilities 41.1 M
Long-Term Debt 40.2 M
Other Non-Current Liabilities 880 K
13.61 %27.46 %25.32 %32.89 %Total Liabilities$122.2m
EFFICIENCY
Earnings Waterfall Agios Pharmaceuticals, Inc.
image
Revenue 36.5 M
Cost Of Revenue 4.16 M
Gross Profit 32.3 M
Operating Expenses 458 M
Operating Income -426 M
Other Expenses -1.1 B
Net Income 674 M
800m800m600m600m400m400m200m200m00(200m)(200m)(400m)(400m)(600m)(600m)36m(4m)32m(458m)(426m)1b674mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
88.59% GROSS MARGIN
88.59%
-1166.47% OPERATING MARGIN
-1166.47%
1845.92% NET MARGIN
1845.92%
43.72% ROE
43.72%
40.51% ROA
40.51%
-24.73% ROIC
-24.73%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Agios Pharmaceuticals, Inc.
image
50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)(350m)(350m)(400m)(400m)(450m)(450m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 674 M
Depreciation & Amortization 5.65 M
Capital Expenditures -1.68 M
Stock-Based Compensation 42.8 M
Change in Working Capital -19.8 M
Others -1.11 B
Free Cash Flow -392 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Agios Pharmaceuticals, Inc.
image
Wall Street analysts predict an average 1-year price target for AGIO of $52.7 , with forecasts ranging from a low of $45 to a high of $56 .
AGIO Lowest Price Target Wall Street Target
45 USD 64.59%
AGIO Average Price Target Wall Street Target
52.7 USD 92.64%
AGIO Highest Price Target Wall Street Target
56 USD 104.83%
Price
Max Price Target
Min Price Target
Average Price Target
6565606055555050454540403535303025252020Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 22
6. Ownership
Insider Ownership Agios Pharmaceuticals, Inc.
image
Sold
0-3 MONTHS
1.22 M USD 7
3-6 MONTHS
2.4 M USD 5
6-9 MONTHS
599 K USD 2
9-12 MONTHS
815 K USD 3
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Agios to Webcast Conference Call of First Quarter Financial Results on May 1, 2025 CAMBRIDGE, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, May 1, 2025, at 8:00 a.m. globenewswire.com - 2 weeks ago
New Strong Sell Stocks for April 8th AFLYY, AGIO and ARLP have been added to the Zacks Rank #5 (Strong Sell) List on April 8, 2025. zacks.com - 3 weeks ago
New Strong Sell Stocks for April 3rd AGIO, CHGG and EFX have been added to the Zacks Rank #5 (Strong Sell) List on April 3, 2025. zacks.com - 4 weeks ago
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer CAMBRIDGE, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the grant of inducement equity awards outside of the Company's 2023 Stock Incentive Plan to its newly appointed Chief Corporate Development & Strategy Officer, Krishnan Viswanadhan. The grants were approved by the Board of Directors effective as of March 5, 2025, as inducements material to Mr. Viswanadhan entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). globenewswire.com - 1 month ago
Agios to Present at Upcoming Investor Conferences CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the following conferences: Leerink Global Healthcare Conference 2025: Fireside chat on Tuesday, March 11, 2025, at 10:50 a.m. globenewswire.com - 1 month ago
Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025 CAMBRIDGE, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the TD Cowen 45th Annual Healthcare Conference on Monday, March 3, 2025, at 10:30 a.m. ET. globenewswire.com - 2 months ago
Agios' Q4 Loss Wider Than Expected, Pyrukynd Drives Revenues AGIO reports mixed fourth-quarter 2024 results. Its sole marketed drug, Pyrukynd, drives revenues year over year. zacks.com - 2 months ago
Agios Pharmaceuticals, Inc. (AGIO) Q4 2024 Earnings Call Transcript Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q4 2024 Earnings Conference Call February 13, 2025 8:00 AM ET Company Participants Brian Goff - CEO Sarah Gheuens - CMO & Head OF R&D Tsveta Milanova - CCO Cecilia Jones - CFO Chris Taylor - VP, IR & Corporate Communications Conference Call Participants Eric Schmidt - Cantor Fitzgerald Divya Rao - TD Cowen Gregory Renza - RBC Capital Markets Greg Harrison - Scotiabank Chris Raymond - Piper Sandler Alec Stranahan - Bank of America Lydia Erdman - Goldman Sachs Tessa Romero - J.P. Morgan Operator Good morning, and welcome to Agios' fourth quarter 2024 conference call. seekingalpha.com - 2 months ago
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue Estimates Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.74 per share versus the Zacks Consensus Estimate of a loss of $1.73. This compares to loss of $1.72 per share a year ago. zacks.com - 2 months ago
Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights – Filed for Regulatory Approval of Mitapivat (PYRUKYND ® ) for the Treatment of Adult Patients with  Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia in U.S.,  European Union, Kingdom of Saudi Arabia and United Arab Emirates;  PDUFA Goal Date of September 7, 2025 – globenewswire.com - 2 months ago
Agios' Phase 3 ACTIVATE-Kids Study of Mitapivat in Children with Pyruvate Kinase (PK) Deficiency Not Regularly Transfused Met Primary Endpoint – ACTIVATE-Kids is the First Study to Demonstrate Efficacy of an Oral Therapy for Children with PK Deficiency Who Are Not Regularly Transfused – globenewswire.com - 2 months ago
Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025 CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, February 13, 2025, at 8:00 a.m. globenewswire.com - 2 months ago
8. Profile Summary

Agios Pharmaceuticals, Inc. AGIO

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 1.57 B
Dividend Yield 0.00%
Description Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Contact 88 Sidney Street, Cambridge, MA, 02139-4169 https://www.agios.com
IPO Date July 24, 2013
Employees 486
Officers Dr. Lewis Clayton Cantley Ph.D. Co-Founder Mr. Brian M. Goff M.B.A. Chief Executive Officer & Director Dr. Craig B. Thompson M.D. Co-Founder Ms. Cecilia Jones Chief Financial Officer Dr. Sarah Gheuens M.D., Ph.D. Chief Medical Officer and Head of Research & Development Dr. Shin-San Su Ph.D. Co-Founder Mr. T. J. Washburn Vice President, Controller & Principal Accounting Officer Ms. Tsveta Milanova Chief Commercial Officer Mr. James William Burns Corporate Secretary & Chief Legal Officer Dr. Tak Wah Mak D.Sc., FRSC, Ph.D. Co-Founder